Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
StimCell Energetics hired Stonegate Capital to boost investor interest in its anti-aging biotech technology.
StimCell Energetics has hired Stonegate Capital Partners to boost institutional investor interest, effective March 12, 2026, under a 12-month agreement.
Stonegate will provide quarterly research, investor relations support, and meeting coordination in exchange for 250,000 shares of common stock, subject to a six-month hold and regulatory compliance.
The move aims to increase visibility for the biotech firm’s eBalance technology, which targets aging, insulin resistance, high blood pressure, neuropathy, and kidney function.
Forward-looking statements are included, with risks noted.
No regulatory review has occurred.
5 Articles
StimCell Energetics contrató a Stonegate Capital para impulsar el interés de los inversores en su tecnología biotecnológica antienvejecimiento.